Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2014

View Archived Issues

Phase I/II results for cell therapy-based replacement of retinal pigment epithelium

Oasmia's Paclical demonstrates positive risk/benefit profile in comparison with Taxol

Clinical response maintained with long-term brodalumab therapy in patients with psoriasis

PNPLA3 gene polymorphism associated with gallbladder cholesterol polyps

Critical Outcome Technologies and MD Anderson Cancer Center to evaluate COTI-2

SomaLogic and Novartis extend proteomics agreement

Addex and the Charcot-Marie-Tooth Association to advance ADX-71441

Asterias Biotherapeutics provides update on grant award from CIRM for AST-OPC1 trial

Phase II HIV treatment ibalizumab receives U.S. orphan drug designation

FDA grants tipelukast orphan drug status for IPF

Athera begins phase I trial of fully human antibody PC-mAb

Early clinical data for maternal immunization with the trivalent GBS vaccine

Aurigene Discovery Technologies discloses new TAK1 inhibitors

Novel anti-staphylococcal enterotoxin B MAbs divulged

In vivo testing of novel GPR-directed [99mTc]demobesin mimics

KU Leuven discloses new viral replication inhibitors for Flaviviridae infections

CHDI Foundation discloses novel HDAC4 inhibitors for Huntington's disease

Bristol-Myers Squibb reports new FFAR4 modulators

Omeros provides update on OMS-824 program

Repros Therapeutics reports results from long-term safety study of Androxal

Companies update development strategies in face of Ebola

GMI-1051 improves efficacy of antibiotic treatments in models of Pseudomonas infection

Relypsa submits NDA to FDA seeking approval of patiromer for hyperkalemia

EMA outlines recent efforts to expedite development of Ebola treatments

Phase III trials of secukinumab in ankylosing spondylitis meet primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...